# Edwards Lifesciences Corp: Form 10-Q for the period ended Sep 30, 2020

- Company: [Edwards Lifesciences Corp](/companies/ew.md) (CIK 1099800)
- Form: 10-Q
- Filed: 2020-10-26
- Accepted by EDGAR: Oct 23, 2020, 19:57 ET
- Period: 2020-09-30
- Accession: 0001099800-20-000024
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1099800/000109980020000024/ew10-qq32020.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1099800/000109980020000024/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $1.14bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $3.19bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-07-01 to 2020-09-30 | $281.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-30 | $784.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $859.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-09-30 | $2.41bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $195.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-01 to 2020-09-30 | $565.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $307.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-30 | $889.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-01 to 2020-09-30 | $357.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-09-30 | $546.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | $39.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | $46.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | $325.2m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | $513.9m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | $0.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-01 to 2020-09-30 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-30 | $0.83 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-01 to 2020-09-30 | 631,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-30 | 628,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | $654.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $293.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2020-01-01 to 2020-09-30 | $625.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-09-30 | $1.02bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $2.98bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $6.80bn | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $846.3m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2020-09-30 | $594.9m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2020-09-30 | $4.21bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 27,082 characters.

### Overview

*The following discussion and analysis contains forward-looking statements within the meaning of the federal securities laws, and should be read in conjunction with the disclosures we make concerning risks and other factors that may affect our business and operating results. See “Note Regarding Forward-Looking Statements” preceding Part I, Item 1 in this Quarterly Report on Form 10-Q.*

We are the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we partner with the world's leading clinicians and researchers and invest in research and development to transform care for those impacted by structural heart disease or who require hemodynamic monitoring during surgery or intensive care. We conduct operations worldwide and are managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Our products are categorized into the following main areas: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural Heart ("Surgical"), and Critical Care.

On May 7, 2020, our Board of Directors declared a three-for-one stock split of our outstanding shares of common stock effected in the form of a stock dividend, distributed on May 29, 2020 to stockholders of record on May 18, 2020. We distributed two newly issued shares of common stock to holders of record of each share of common stock to effect the stock split. All applicable share and per-share amounts in this “Management’s *Discussion and Analysis of Financial Condition and Results of Operations”* have been retroactively adjusted to give effect to this stock split.

#### Financial Highlights and COVID-19

In March 2020, the World Health Organization categorized the Coronavirus disease 2019 ("COVID-19") as a pandemic. COVID-19 continues to spread throughout the United States and other countries across the world, and the duration and severity of its effects are currently unknown. The global pandemic has adversely impacted and is likely to further adversely impact nearly all aspects of our business and markets, including our workforce and the operations of our customers, suppliers, and business partners. Our priority has been to support our clinician partners, protect the well-being of our employees, and maintain continuous access to our life-saving technologies while offering front-line in-hospital support. Our manufacturing operations have continued to respond to impacts related to COVID-19, and we have been able to supply our technologies around the world. Across the organization, we are proactively managing inventory, assessing alternative logistics options, and closely monitoring the supply of components.

TAVR and Surgical procedure volumes varied greatly since the middle of March 2020 by geography, and even by hospital, as patients and their physicians analyzed the trade-off between aortic stenosis and their concern for COVID-19. In the last few weeks of the first quarter of 2020, procedure volumes related to our TAVR and Surgical products dropped significantly. During the second and third quarters of 2020, procedure volumes improved. In the second quarter of 2020, we also started to progressively resume patient enrollment in all clinical trials that were voluntarily paused or slowed at the end of the first quarter of 2020, and we are now enrolling patients at pre-COVID rates. In Critical Care, there was greater demand in Europe for our pressure monitoring products, but demand for other Critical Care products began to decrease at the end of the first quarter of 2020 due to COVID-19, and that trend continued through the third quarter of 2020.

Despite the challenges associated with COVID-19, our net sales for the first nine months of 2020 were $3.2 billion, representing an increase of $20.7 million over the first nine months of 2019, driven by sales growth of our TAVR products.

Our gross profit increase was driven by a charge recorded during the three and nine months ended September 30, 2019 of $26.9 million and $73.1 million, respectively, primarily comprised of the write off of inventory related to strategic decisions regarding our TAVR portfolio, including the decision to discontinue our CENTERA program.

The increase from the prior quarter-to-date period in our diluted earnings per share was driven by our increased sales growth as well as reduced spending due to COVID-19. The decrease from the prior year-to-date period in our diluted earnings per share was driven by an after-tax charge of $306.9 million in the second quarter of 2020 to settle certain patent litigation related to transcatheter mitral and tricuspid repair products. For further information, see Notes 3 and 9 to the "*Consolidated Condensed Financial Statements."*

We are closely monitoring the impact of COVID-19 on all aspects of our business and geographies, including its impact on our customers, employees, suppliers, vendors, business partners and distribution channels. The extent to which the COVID-19 global pandemic impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and are difficult to predict; these developments include, but are not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or address its impact, U.S. and foreign government actions to respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may continue to experience materially adverse impacts on our financial condition and results of operations.

#### Healthcare Environment, Opportunities, and Challenges

The medical technology industry is highly competitive and continues to evolve. Our success is measured both by the development of innovative products and the value we bring to our stakeholders. We are committed to developing new technologies and providing innovative patient care, and we are committed to defending our intellectual property in support of those developments. In the first nine months of 2020, we invested 17.7% of our net sales in research and development.

### New Accounting Standards

For information on new accounting standards, see Note 1 to the "*Consolidated Condensed Financial Statements."*

### Results of Operations

### Net Sales Trends

(dollars in millions)

|  | Three Months Ended September 30, 2020 | Percent Change 2019 | Change | Percent Change 2020 | Nine Months Ended September 30, 2019 | Change |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| United States | $662.0 | $647.8 | $14.2 | 2.2% | $1,845.6 | $1,835.5 | $10.1 | 0.6% |
| Europe | 253.8 | 222.6 | 31.2 | 13.9% | 707.8 | 699.0 | 8.8 | 1.2% |
| Japan | 113.9 | 112.9 | 1.0 | 0.8% | 330.7 | 324.4 | 6.3 | 1.9% |
| Rest of World | 111.2 | 110.7 | 0.5 | 0.7% | 310.5 | 315.0 | (4.5) | (1.4)% |
| International | 478.9 | 446.2 | 32.7 | 7.3% | 1,349.0 | 1,338.4 | 10.6 | 0.8% |
| Total net sales | $1,140.9 | $1,094.0 | $46.9 | 4.3% | $3,194.6 | $3,173.9 | $20.7 | 0.7% |

International net sales include the impact of foreign currency exchange rate fluctuations. The impact of foreign currency exchange rate fluctuations on net sales is not necessarily indicative of the impact on net income due to the corresponding effect of foreign currency exchange rate fluctuations on international manufacturing and operating costs, and our hedging activities.

### Net Sales by Product Group

(dollars in millions)

|  | Three Months Ended September 30, 2020 | Percent Change 2019 | Change | Percent Change 2020 | Nine Months Ended September 30, 2019 | Change |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Transcatheter Aortic Valve Replacement | $744.6 | $700.0 | $44.6 | 6.4% | $2,081.1 | $1,975.4 | $105.7 | 5.3% |
| Transcatheter Mitral and Tricuspid Therapies | 12.1 | 9.7 | 2.4 | 23.7% | 28.7 | 21.0 | 7.7 | 36.5% |
| Surgical Structural Heart | 203.3 | 204.1 | (0.8) | (0.3)% | 557.6 | 636.6 | (79.0) | (12.4)% |
| Critical Care | 180.9 | 180.2 | 0.7 | 0.4% | 527.2 | 540.9 | (13.7) | (2.5)% |
| Total net sales | $1,140.9 | $1,094.0 | $46.9 | 4.3% | $3,194.6 | $3,173.9 | $20.7 | 0.7% |

### Transcatheter Aortic Valve Replacement

Net sales of TAVR products increased for the three and nine months ended September 30, 2020 driven by higher sales of the *Edwards SAPIEN 3 Ultra System* following its regulatory approval in the United States (December 2018) and in Europe (November 2018). Our sales for the nine months ended September 30, 2020 were also negatively impacted by the COVID-19 pandemic. Our procedure volumes dropped significantly beginning in March 2020 due to COVID-19, and began to steadily improve beginning in May 2020.

The launch of the *Edwards SAPIEN 3 Ultra System* continued to be very positive in the first nine months of 2020. In the first quarter of 2020, to ensure the safety of our employees and clinician partners from the threat of COVID-19, we decided to pause proctoring at centers that were not already trained on the *Edwards SAPIEN 3 Ultra System*. In the second quarter of 2020, we resumed training.

### Transcatheter Mitral and Tricuspid Therapies

Net sales of TMTT products increased for the three and nine months ended September 30, 2020 due primarily to sales in Europe of *PASCAL*, which received CE Mark in February 2019. Our sales in nine months ended September 30, 2020 were also negatively impacted by the COVID-19 pandemic. Our procedure volumes for *PASCAL* dropped significantly in April 2020 due to COVID-19, and began to improve beginning in May 2020.

At the end of March 2020, we temporarily paused new enrollments in our active pivotal clinical trials of transcatheter mitral and tricuspid therapies in response to the COVID-19 response around the globe. In the second quarter of 2020, we began resuming enrollments and are now enrolling patients at pre-COVID rates. In May 2020, we received CE Mark for the *PASCAL Ace* implant system for mitral and tricuspid repair.

### Surgical Structural Heart

Net sales of Surgical products decreased for the three and nine months ended September 30, 2020 due primarily to decreased sales of aortic tissue valves, primarily in the United States and Europe, due to the impact of COVID-19. The ongoing adoption of TAVR also contributed to the decrease in United States surgical aortic valve sales. These decreases were partially offset by increased sales of the *INSPIRIS RESILIA* aortic valve, primarily in the United States. Increased and improved management of intensive care unit capacity, as well as prioritization of heart surgery in many hospitals, contributed to rebounding procedure volumes late in the second quarter of 2020.

In Europe, our *HARPOON Beating Heart Mitral Valve Repair System* became available commercially at the end of 2019, and the first commercial case was successfully completed in Europe in the second quarter of 2020. In addition, we received United States Food and Drug Administration approval in April 2020 to begin our U.S. pivotal investigational device exemption study. *HARPOON* offers the potential for earlier treatment of degenerative mitral valve disease, with faster recovery and more consistent outcomes for surgical patients.

### Critical Care

The decrease in net sales of Critical Care products for the nine months ended September 30, 2020 was driven by a decline in sales of our enhanced surgical recovery products, primarily in the United States, as many surgical procedures were delayed due to COVID-19 beginning in March 2020. We also experienced a decline in orders of our *HemoSphere* advanced monitoring platform in the United States as hospitals limited their capital spending due to COVID-19. Foreign exchange rate fluctuations decreased net sales for the nine months ended September 30, 2020 by $4.4 million due to the weakening of multiple currencies, primarily the Euro, against the United States dollar.

These decreases in net sales during the nine months ended September 30, 2020 were partially offset by increased demand for our pressure monitoring products, primarily in Europe. In addition, our sales for the three and nine months ended September 30, 2020 included $5.6 million and $15.7 million, respectively, related to CAS Medical Systems, Inc. ("CASMED"), which we acquired on April 18, 2019. CASMED is a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain.

### Gross Profit

The increase in gross profit as a percentage of net sales for the three and nine months ended September 30, 2020 was driven primarily by:

- a charge in the three and nine months ended September 30, 2019 of $26.9 million and $73.1 million, respectively, related to strategic decisions regarding our TAVR portfolio, including the decision to discontinue our CENTERA program; and
- manufacturing efficiencies in the three months ended September 30, 2020;

partially offset by:

- a 1.4 percentage point and 0.8 percentage point decrease in the three and nine months ended September 30, 2020, respectively, due to the impact of foreign currency exchange rate fluctuations, including the settlement of foreign currency hedging contracts; and
- incremental costs associated with COVID-19.

### Selling, General, and Administrative ("SG&A") Expenses

SG&A expenses increased for the three months ended September 30, 2020 due primarily to increased sales and marketing expenses related to transcatheter structural heart field personnel, primarily in the United States, partially offset by decreased costs associated with COVID-19. SG&A expenses decreased for the nine months ended September 30, 2020 due to decreased sales, marketing and travel-related expense associated with COVID-19, and the impact of foreign currency, which decreased expenses by $5.5 million due to the strengthening of the United States dollar against multiple currencies, primarily the Euro. These decreases for the nine months ended September 30, 2020 were partially offset by increased sales and marketing expenses related to transcatheter structural heart field personnel, primarily in the United States.

### Research and Development ("R&D") Expenses

R&D expenses were flat for the three months ended September 30, 2020 primarily due to increased spending on transcatheter mitral valve replacement clinical trials, offset by decreased spending on transcatheter aortic valve clinical trials and decreased travel and other expenses associated with COVID-19. The increase in R&D expenses for the nine months ended September 30, 2020 was primarily due to investments in our transcatheter mitral and tricuspid therapies, partially offset by decreased spending on transcatheter aortic valve clinical trials.

### Change in Fair Value of Contingent Consideration Liabilities, net

The change in fair value of contingent consideration liabilities resulted in income of $9.0 million and $2.3 million for the three months ended September 30, 2020 and 2019, respectively, and expense of $8.4 million and $12.4 million for the nine months ended September 30, 2020 and 2019, respectively. The changes in fair value were primarily driven by changes in the projected probability and timing of milestone achievements, and the projected timing of cash inflows, partially offset by the accretion of interest due to the passage of time, and for the nine months ended September 30, 2020, discount rates (which decreased significantly in the first quarter of 2020). For further information, see Note 6 to the "*Consolidated Condensed Financial Statements."*

### Special Charge

For information on the $24.0 million special charge recorded during the nine months ended September 30, 2019, see Note 4 to the "*Consolidated Condensed Financial Statements."*

### Other Income, net

(in millions)

|  | Three Months Ended September 30, 2020 | 2019 | Nine Months Ended September 30, 2020 | 2019 |
| --- | ---: | ---: | ---: | ---: |
| Foreign exchange gains, net | $(5.5) | $(1.0) | $(9.2) | $(4.6) |
| Loss (gain) on investments | 0.2 | (1.6) | 0.8 | (1.2) |
| CASMED earn-out on sale of assets | — | (2.0) | — | (2.0) |
| Other | (0.4) | — | 1.1 | — |
| Other income, net | $(5.7) | $(4.6) | $(7.3) | $(7.8) |

32

The net foreign exchange gains relate primarily to the foreign currency fluctuations in our global trade and intercompany receivable and payable balances, partially offset by the gains and losses on derivative instruments intended as an economic hedge of those exposures.

The loss (gain) on investments primarily represents our net share of gains and losses in investments accounted for under the equity method, and realized gains and losses on investments in equity securities.

The CASMED earn-out relates to a sales performance obligation by an entity that purchased one of CASMED's

discontinued product lines in 2017.

### Provision for Income Taxes

The provision for income taxes consists of provisions for federal, state, and foreign income taxes. We operate in an international environment with significant operations in various locations outside the United States which have statutory tax rates typically lower than the United States tax rate. Accordingly, the consolidated income tax rate is a composite rate reflecting the earnings in the various locations and the applicable rates.

Our effective income tax rate was 10.7% and 8.9% for the three months ended September 30, 2020 and 2019, respectively, and 8.3% and 9.9% for the nine months ended September 30, 2020 and 2019, respectively. The fluctuation in the effective rates between the nine months ended September 30, 2020 and 2019 is primarily due to the impact of the litigation settlement agreement (the "Settlement Agreement") with Abbott Laboratories (see Notes 3 and 9 to the "*Consolidated Condensed Financial Statements*"). The effective rates for the nine months ended September 30, 2020 and 2019 were also lower than the federal statutory rate of 21% primarily due to (1) the tax benefit from employee share-based compensation, (2) foreign earnings taxed at lower rates, and (3) Federal and California research and development credits.

We strive to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While we have accrued for matters we believe are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated financial statements. Furthermore, we may later decide to challenge any assessments, if made, and may exercise our right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. We believe that adequate amounts of tax and related penalty and interest have been provided in income tax expense for any adjustments that may result from our uncertain tax positions. For further information, see Note 12 to the "*Consolidated Condensed Financial Statements."*

The Internal Revenue Service began its examination of the 2015 and 2016 tax years during the fourth quarter of 2018 and its examination of the 2017 tax year during the first quarter of 2019. At September 30, 2020, all material state, local, and foreign income tax matters have been concluded for years through 2010.

During 2018, we executed an Advance Pricing Agreement ("APA") between the United States and Switzerland governments for tax years 2009 through 2020 covering various transfer pricing matters. Certain intercompany transactions covering tax years 2015 through 2020 were not resolved and those related tax positions remain uncertain. These transfer pricing matters may be significant to our consolidated financial statements. Based upon the information currently available and numerous possible outcomes, we cannot reasonably estimate what, if any, changes in our existing uncertain tax positions may occur in the next 12 months and, therefore, have recorded the gross uncertain tax positions as a long-term liability.

In addition, we executed other APAs as follows: during 2017, an APA between the United States and Japan covering tax years 2015 through 2019; and during 2018, APAs between Japan and Singapore and between Switzerland and Japan covering tax years 2015 through 2019. We have filed or intend to file to renew these APAs for the years 2020 and forward. The execution of some or all of these APAs depends on a number of variables outside of our control.

### Liquidity and Capital Resources

Our sources of cash liquidity include cash and cash equivalents, short-term investments, amounts available under credit facilities, and cash from operations. We believe that these sources are sufficient to fund the current requirements of working capital, capital expenditures, and other financial commitments for the next twelve months. However, we periodically consider various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other market conditions.

As of September 30, 2020, cash and cash equivalents and short-term investments held in the United States and outside the United States were $770.0 million and $525.3 million, respectively.

In April 2018, we entered into a Five-Year Credit Agreement ("the Credit Agreement") which matures on April 28, 2023. The Credit Agreement provides up to an aggregate of $750.0 million in borrowings in multiple currencies. Subject to certain terms and conditions, we may increase the amount available under the Credit Agreement by up to an additional $250.0 million in the aggregate. As of September 30, 2020, there were no borrowings outstanding under the Credit Agreement.

In June 2018, we issued $600.0 million of 4.300% fixed-rate unsecured senior notes (the "2018 Notes") due June 15, 2028. As of September 30, 2020, the total carrying value of the 2018 Notes was $594.9 million.

From time to time, we repurchase shares of our common stock under share repurchase programs authorized by the Board of Directors. We consider several factors in determining when to execute share repurchases, including, among other things, expected dilution from stock plans, cash capacity, and the market price of our common stock. During the nine months ended September 30, 2020, under the Board authorized program, we repurchased a total of 3.0 million shares at an aggregate cost of $614.7 million, and as of September 30, 2020, we had remaining authority to purchase $625.0 million of our common stock.

Certain of our business acquisitions involve contingent consideration arrangements. Payment of additional consideration in the future may be required, contingent upon the acquired company reaching certain performance milestones, such as attaining specified revenue levels, achieving product development targets, or obtaining regulatory approvals. For further information, see Note 6 to the "*Consolidated Condensed Financial Statements."*

On July 12, 2020, we reached the Settlement Agreement with Abbott Laboratories to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The Settlement Agreement resulted in us recording an estimated $367.9 million pretax charge in June 2020 related to past damages. In addition, we will incur royalty expenses through May 2024 totaling an estimated $100 million. We made a one-time $100.0 million payment to Abbott in July 2020, and will make quarterly payments in future years. For further information, see Notes 3 and 9 to the "*Consolidated Condensed Financial Statements."*

At September 30, 2020, there had been no material changes in our significant contractual obligations and commercial commitments as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

### Consolidated Cash Flows - For the nine months ended September 30, 2020 and 2019:

Net cash flows provided by **operating activities** of $654.3 million for the nine months ended September 30, 2020 decreased $125.7 million over the same period last year primarily due to lower operating profits in 2020 and a payment of $100.0 million for a litigation settlement, partially offset by a payment of $180.0 million in 2019 for a litigation settlement. For further information, see Notes 3 and 9 to the "*Consolidated Condensed Financial Statements."*

Net cash used in **investing activities** of $271.2 million for the nine months ended September 30, 2020 consisted primarily of capital expenditures of $293.8 million, partially offset by net proceeds from investments of $58.6 million.

Net cash used in investing activities of $150.5 million for the nine months ended September 30, 2019 consisted primarily of (1) capital expenditures of $182.9 million, (2) an $100.2 million net cash payment associated with the acquisition of CASMED in April 2019, (3) a $35.0 million payment for an option to acquire a company, and (4) a $24.0 million payment to acquire certain early-stage transcatheter intellectual property and associated clinical and regulatory experience, partially offset by net proceeds from investments of $194.7 million.

Net cash used in **financing activities** of $528.3 million for the nine months ended September 30, 2020 consisted primarily of purchases of treasury stock of $625.2 million, partially offset by proceeds from stock plans of $103.5 million.

Net cash used in financing activities of $152.6 million for the nine months ended September 30, 2019 consisted primarily of purchases of treasury stock of $263.3 million, partially offset by proceeds from stock plans of $125.5 million.

### Critical Accounting Policies and Estimates

The consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated condensed financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 38-41 in Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations,*" of our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes from the information discussed therein.

## Market risk

As filed, 1,226 characters.

### Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk

For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A "*Quantitative and Qualitative Disclosures About Market Risk*" on pages 42-44 of our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes from the information discussed therein.

### Investment Risk

We are exposed to investment risks related to changes in the underlying financial condition and credit capacity of certain of our investments. As of September 30, 2020, we had $837.0 million of investments in fixed-rate debt securities of various companies, of which $565.7 million were long-term. In addition, we had $33.3 million of investments in equity instruments of public and private companies. Should these companies experience a decline in financial performance, financial condition, or credit capacity, or fail to meet certain development milestones, including as a result of the impact of COVID-19 on their business or operations or otherwise, a decline in the investments' value may occur, resulting in unrealized or realized losses.

## Controls and procedures

As filed, 1,803 characters.

**Evaluation of Disclosure Controls and Procedures.** Our management, including the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2020. Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded as of September 30, 2020 that our disclosure controls and procedures are designed at a reasonable assurance level and effective in providing reasonable assurance that the information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control Over Financial Reporting.** There have been no changes in our internal controls over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We have not experienced any material impact to our internal control over financial reporting despite the fact that many of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the potential impact of COVID-19 on our internal controls to minimize the impact on their design and operating effectiveness.

## Risk factors

As filed, 342 characters.

A description of the risk factors associated with our business is contained in the “Risk Factors” section of our Annual Report on Form 10-K for our fiscal year ended December 31, 2019 and of our Quarterly Report on Form 10-Q for our quarter ended March 31, 2020. There have been no material changes to our Risk Factors as previously reported.

Filed Oct 26, 2020.
Source: SEC EDGAR, the filing index for accession 0001099800-20-000024. Last ingested by Listed: Nov 15, 2026, 03:19 ET. No prices; not investment advice.
